Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17137311 | USE OF TREZASTILBENOSIDE IN MANUFACTURE OF PRODUCT FOR TREATING AND/OR PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | December 2020 | September 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17129366 | METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS | December 2020 | April 2023 | Allow | 28 | 1 | 0 | No | No |
| 17127107 | RESTORING PHYSIOLOGY WITH SMALL MOLECULE MIMICS OF MISSING PROTEINS | December 2020 | June 2024 | Abandon | 42 | 2 | 0 | No | Yes |
| 17124606 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17118754 | USE OF POLY ALPHA-1,3-GLUCAN ETHERS AS VISCOSITY MODIFIERS | December 2020 | December 2023 | Allow | 36 | 2 | 0 | No | No |
| 16972391 | METHOD OF TREATMENT WITH TRADIPITANT | December 2020 | September 2024 | Abandon | 45 | 2 | 0 | No | No |
| 16972184 | METHODS FOR TREATING MUSCULAR DYSTROPHIES | December 2020 | May 2024 | Allow | 42 | 2 | 0 | No | No |
| 17109970 | SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASE | December 2020 | February 2023 | Allow | 27 | 1 | 0 | No | No |
| 17104414 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | November 2020 | May 2023 | Allow | 29 | 2 | 0 | No | No |
| 17100523 | MODIFIED BIOPOLYMERS AND METHODS OF PRODUCING AND USING THE SAME | November 2020 | January 2024 | Abandon | 38 | 3 | 0 | Yes | No |
| 16952557 | LIPONUCLEOTIDE-BASED THERAPY FOR ARDS | November 2020 | August 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17099306 | SYNTHETIC COMPOSITION AND METHOD FOR MODULATING BRAIN FUNCTION AND BEHAVIOUR | November 2020 | February 2023 | Allow | 27 | 1 | 0 | No | No |
| 17055937 | INORGANIC SALTS OF NICOTINAMIDE MONONUCLOETIDE AS ANTI-AGING AGENTS | November 2020 | July 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17094962 | Preparation Method of Amylodextrin | November 2020 | November 2022 | Allow | 24 | 1 | 0 | No | No |
| 17049825 | FINE CELLULOSE FIBER AND METHOD FOR PRODUCING SAME | October 2020 | December 2022 | Allow | 26 | 2 | 0 | Yes | No |
| 17047313 | COMPOUND, METHOD OF PRODUCTION AND USES THEREOF | October 2020 | August 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17046463 | Antibacterial Compounds | October 2020 | February 2023 | Allow | 28 | 2 | 0 | No | No |
| 17046595 | IMMUNIGENIC ALPHA-BRANCHED TREHALOSE-DIESTERS | October 2020 | April 2024 | Allow | 42 | 1 | 1 | No | No |
| 17045283 | SYNTHESIS OF NOVEL XYLOSE FREE OCCIDIOFUNGIN ANALOGUES AND METHODS OF USING THEM | October 2020 | April 2024 | Allow | 42 | 1 | 1 | No | No |
| 17045343 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | October 2020 | March 2024 | Allow | 41 | 1 | 0 | No | No |
| 17061821 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | October 2020 | June 2022 | Allow | 20 | 1 | 0 | No | No |
| 17043955 | COMBINATION OF A UBIQUITIN-CONJUGATING ENZYME COMPLEX INHIBITOR AND ANTIHYPERTENSIVE AND/OR HYPOGLYCEMIC DRUGS IN DIABETIC KIDNEY DISEASE | September 2020 | May 2024 | Allow | 43 | 2 | 0 | No | No |
| 17025947 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | September 2020 | November 2023 | Allow | 37 | 1 | 0 | Yes | No |
| 17021909 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | September 2020 | March 2023 | Allow | 30 | 3 | 0 | No | No |
| 16981242 | 3'',5''-DIMETHOXYBENZOYL-3'-AMINO-3'-DEOXYADENOSINE-5'-TRIPHOSPHATES AND PHARMACEUTICAL USES THEREOF | September 2020 | May 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 17010648 | METHODS OF TREATMENT AND MAINTENANCE THERAPY FOR BLADDER CANCER USING GEMCITABINE | September 2020 | August 2022 | Allow | 23 | 3 | 0 | No | No |
| 17005854 | OLIGONUCLEOTIDE SYNTHESIZER | August 2020 | August 2022 | Allow | 24 | 2 | 0 | No | No |
| 16970753 | IMMUNOGENIC TREHALOSE COMPOUNDS AND USES THEREOF | August 2020 | October 2022 | Allow | 25 | 1 | 0 | No | No |
| 16968201 | PROCESS FOR THE PREPARATION OF DALTEPARIN SODIUM | August 2020 | July 2022 | Allow | 23 | 1 | 0 | No | No |
| 16967924 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | August 2020 | March 2023 | Allow | 31 | 2 | 0 | Yes | No |
| 16985404 | COMBINATION THERAPY FOR TREATING CANCER | August 2020 | February 2022 | Allow | 18 | 0 | 1 | No | No |
| 16983760 | Compositions Comprising Galactose-Pronged Polysaccharides | August 2020 | April 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16966857 | The use of Pulsatilla chinensis extract in the preparation of drugs for treatment of viral and/or bacterial diseases | July 2020 | September 2022 | Allow | 25 | 2 | 0 | No | No |
| 16939849 | PROCESS FOR THE PREPARATION OF GALNAC OLIGONUCLEOTIDE CONJUGATES | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16940039 | PHOSPHORAMIDITE SYNTHONES FOR THE SYNTHESIS OF SELF-NEUTRALIZING OLIGONUCLEOTIDE COMPOUNDS | July 2020 | September 2022 | Allow | 26 | 1 | 0 | No | No |
| 16938826 | COMPOUNDS AND METHODS FOR MODULATING GFAP | July 2020 | January 2023 | Allow | 30 | 1 | 0 | No | No |
| 16929690 | COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER | July 2020 | March 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16921562 | ANIMAL THERAPEUTIC AND FEED COMPOSITIONS AND METHODS OF USE | July 2020 | March 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16959519 | SELECTIVE PARP1 INHIBITORS TO TREAT CANCER | July 2020 | May 2024 | Abandon | 46 | 4 | 0 | No | No |
| 16904270 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | June 2020 | May 2023 | Abandon | 34 | 3 | 0 | No | No |
| 16771814 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | June 2020 | February 2023 | Allow | 32 | 2 | 1 | No | No |
| 16771098 | PROCESS FOR THE PREPARATION OF LOW MOLECULAR WEIGHT HEPARIN | June 2020 | December 2021 | Allow | 18 | 1 | 0 | No | No |
| 16769960 | TREATMENT OF STEROID-RESISTANT DISEASE USING AN ANTHOCYANIN AND A CORTICOSTEROID | June 2020 | February 2022 | Abandon | 21 | 1 | 0 | No | No |
| 16890752 | POLYNUCLEOTIDE CAPTURE MATERIALS, AND SYSTEMS USING SAME | June 2020 | October 2021 | Allow | 16 | 3 | 0 | Yes | No |
| 16884340 | Method for Preparing Short-Clustered Dextrin | May 2020 | October 2021 | Allow | 17 | 1 | 0 | No | No |
| 16880414 | Application of Macrolide Antibiotic in Blocking Influenza Virus Infection | May 2020 | August 2022 | Abandon | 27 | 2 | 0 | Yes | No |
| 16764260 | COMPOSITIONS AND METHODS USING OLEUROPEIN OR CURCUMIN FOR MUSCLE QUALITY AND/OR MUSCLE MASS | May 2020 | January 2024 | Abandon | 44 | 6 | 0 | Yes | No |
| 16872949 | CHEMICAL COMPOUNDS | May 2020 | December 2021 | Allow | 19 | 1 | 0 | No | No |
| 16866397 | DETECTION OF OLIGOSACCHARIDES | May 2020 | March 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16761304 | NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR | May 2020 | December 2022 | Abandon | 31 | 2 | 0 | No | Yes |
| 16761027 | BRARTEMICIN ANALOGUES | May 2020 | July 2022 | Allow | 27 | 1 | 0 | No | No |
| 16760870 | CELLULOSE ETHER-LACTAM HYBRID POLYMERS, COMPOSITIONS, AND METHODS FOR PREPARING AND USING THE HYBRID POLYMERS | April 2020 | April 2023 | Allow | 36 | 2 | 0 | No | No |
| 16760380 | CD73 INHIBITORS | April 2020 | October 2021 | Allow | 18 | 1 | 0 | No | No |
| 16758532 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | April 2020 | January 2023 | Allow | 33 | 3 | 0 | No | No |
| 16856559 | GELLING DEXTRAN ETHERS | April 2020 | August 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16856342 | METHODS FOR REDUCING THE WEIGHT LOSS OR INCREASING THE WEIGHT OF A FELINE IN NEED THEREOF | April 2020 | April 2023 | Abandon | 36 | 2 | 0 | No | Yes |
| 16757996 | SUCKABLE AND/OR MELT-IN-MOUTH TABLET BASED ON HYALURONIC ACID AND CHONDROITIN SULPHATE AND SALTS THEREOF FOR USE IN THE TREATMENT OF A SUBPOPULATION OF GERD PATIENTS | April 2020 | December 2023 | Abandon | 43 | 4 | 0 | No | No |
| 16853670 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | April 2020 | February 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16756855 | Modified oligonucleotides and compound that can be used for synthesizing same | April 2020 | April 2022 | Allow | 24 | 2 | 0 | No | No |
| 16838972 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | April 2020 | November 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16836132 | COMPOUNDS TARGETING PRMT5 | March 2020 | July 2021 | Allow | 16 | 1 | 0 | No | No |
| 16821762 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | March 2020 | July 2020 | Allow | 4 | 1 | 0 | Yes | No |
| 16820126 | MIXTURES OF HUMAN MILK OLIGOSACCHARIDES COMPRISING 3 '-O-SIALYLLACTOSE | March 2020 | July 2021 | Allow | 16 | 1 | 0 | No | No |
| 16819889 | MAILLARD REACTION PRODUCTS AS INHIBITORS OF AGGREGATIBACTER ACTINOMYCETEMCOMITANS | March 2020 | January 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16647282 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | March 2020 | August 2023 | Abandon | 41 | 4 | 0 | No | No |
| 16812888 | ORAL B12 THERAPY | March 2020 | November 2021 | Abandon | 20 | 4 | 0 | No | No |
| 16812745 | METHODS OF TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION | March 2020 | February 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16812233 | LNA-G Process | March 2020 | September 2022 | Allow | 31 | 2 | 0 | No | No |
| 16643689 | Compounds and Methods for Treating Cancer | March 2020 | October 2021 | Allow | 19 | 1 | 0 | No | No |
| 16805795 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | March 2020 | November 2023 | Allow | 44 | 7 | 0 | Yes | Yes |
| 16643127 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | February 2020 | May 2023 | Allow | 39 | 3 | 0 | No | No |
| 16642665 | Nanofibrillated Cellulose Fibers | February 2020 | April 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16642835 | Treatment Regimens | February 2020 | October 2023 | Abandon | 44 | 3 | 0 | No | No |
| 16641888 | A METHOD FOR PRODUCING A POLYPHENOLIC COMPOSITION FROM BARLEY MALT | February 2020 | September 2022 | Allow | 30 | 1 | 1 | No | No |
| 16640482 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | February 2020 | August 2022 | Allow | 30 | 3 | 0 | No | No |
| 16639425 | Maltodextrin and Process of Making Same | February 2020 | October 2022 | Allow | 32 | 3 | 0 | Yes | No |
| 16790810 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | February 2020 | April 2022 | Allow | 26 | 4 | 0 | Yes | No |
| 16791808 | IP AND IP ANALOGS DOSAGE REGIMENS FOR THE TREATMENT OF ECTOPIC CALCIFICATIONS | February 2020 | December 2020 | Allow | 10 | 1 | 0 | Yes | No |
| 16473168 | HIGH MOLECULAR WEIGHT GLUCAN HAVING LOW DIGESTION RATE | February 2020 | April 2021 | Allow | 22 | 0 | 0 | Yes | No |
| 16638563 | PURIFICATION AGENT FOR SUGAR CHAIN OR GLYCOPEPTIDE, AND USE THEREOF | February 2020 | June 2021 | Allow | 16 | 3 | 0 | No | No |
| 16637766 | MEDICAL APPLICATION OF COMPOSITION OF FRUCTOSE-1,6-BISPHOSPHATE AND BLOOD CONCENTRATION STABILIZER THEREOF | February 2020 | June 2022 | Abandon | 28 | 2 | 0 | Yes | No |
| 16780073 | PRESERVED COMPOSITIONS CONTAINING HYALURONIC ACID OR A PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF AND RELATED METHODS | February 2020 | October 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16780754 | TOPICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL LESIONS | February 2020 | September 2021 | Allow | 19 | 2 | 0 | Yes | No |
| 16635891 | USE OF STEROIDAL GLYCOSIDES, PHARMACEUTICAL FORMULATIONS, USE OF FURCRAEA FOETIDA PLANT EXTRACTS, PROCESS FOR PRODUCING FURCRAEA FOETIDA PLANT EXTRACTS AND METHOD FOR TREATING SKIN DISORDERS | January 2020 | March 2022 | Allow | 26 | 2 | 0 | No | No |
| 16634654 | Combination of MIDH1 Inhibitors and DNA Hypomethylating Agents (HMA) | January 2020 | June 2022 | Abandon | 28 | 2 | 0 | Yes | No |
| 16773164 | METHOD FOR PRODUCING HYDROGELS | January 2020 | May 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16634523 | USE OF RHAMNOSE AND DERIVATIVES THEREOF AS ANTIFUNGAL AGENTS | January 2020 | August 2021 | Allow | 19 | 1 | 0 | No | No |
| 16752400 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | January 2020 | May 2021 | Allow | 16 | 1 | 0 | No | No |
| 16750565 | FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT | January 2020 | May 2021 | Allow | 16 | 1 | 0 | No | No |
| 16632983 | VACCINE ADJUVANT AND MICRONEEDLE PREPARATION | January 2020 | June 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16748080 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | January 2020 | August 2022 | Abandon | 30 | 2 | 0 | Yes | No |
| 16630784 | CROSS-LINKED MALTODEXTRINS FOR THE ORAL DELIVERY OF BIOLOGICAL ACTIVES | January 2020 | August 2023 | Allow | 43 | 4 | 1 | No | No |
| 16739663 | METHOD FOR TREATING TRAUMATIC BRAIN INJURY | January 2020 | May 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16629002 | PREPARATION OF PULSATILLA SAPONIN B4 FOR INJECTION | January 2020 | February 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 16627729 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | December 2019 | June 2023 | Allow | 41 | 3 | 1 | No | No |
| 16625342 | ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES | December 2019 | January 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16625525 | PROTON ACTIVATED ATOMIC MEDICINE | December 2019 | March 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16615829 | ANTI-INFLAMMATORY COMPOSITION FOR IMPROVING INTESTINAL NUTRITIONAL METABOLISM FUNCTIONS AND INTESTINAL MICROECOLOGY, FOOD CONTAINING SAME, AND APPLICATION THEREOF | December 2019 | January 2022 | Allow | 26 | 4 | 0 | Yes | No |
| 16716511 | DICLOFENAC FORMULATIONS AND METHODS OF USE | December 2019 | December 2022 | Allow | 36 | 4 | 0 | No | No |
| 16622641 | COMPOSITION COMPRISING MANNOSE OLIGOSACCHARIDE AND PROCESS FOR MAKING SAME AND USE THEREOF | December 2019 | September 2022 | Allow | 33 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OLSON, ERIC.
With a 10.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 5.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner OLSON, ERIC works in Art Unit 1623 and has examined 797 patent applications in our dataset. With an allowance rate of 51.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner OLSON, ERIC's allowance rate of 51.7% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by OLSON, ERIC receive 2.19 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by OLSON, ERIC is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -24.2% benefit to allowance rate for applications examined by OLSON, ERIC. This interview benefit is in the 2% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 18.9% of applications are subsequently allowed. This success rate is in the 21% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.4% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 76.7% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 63.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.9% are granted (fully or in part). This grant rate is in the 48% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 4.0% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.